|
1
|
Löwenberg B, Downing JR and Burnett A:
Acute myeloid leukemia. N Engl J Med. 1999:1051–1062. 1999.
View Article : Google Scholar
|
|
2
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Coombs C, Tavakkoli M and Tallman M: Acute
promyelocytic leukemia: Where did we start, where are we now, and
the future. Blood Cancer J. 5:e3042015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Tallman MS, Gilliland DG and Rowe JM: Drug
therapy for acute myeloid leukemia. Blood. 106:1154–1163. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Löwenberg B: Prognostic factors in acute
myeloid leukaemia. Best Pract Res Clin Haematol. 14:65–75. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bloomfield CD, Lawrence D, Byrd JC,
Carroll A, Pettenati MJ, Tantravahi R, Patil SR, Davey FR, Berg DT,
Schiffer CA, et al: Frequency of prolonged remission duration after
high-dose cytarabine intensification in acute myeloid leukemia
varies by cytogenetic subtype. Cancer Res. 58:4173–4179.
1998.PubMed/NCBI
|
|
8
|
Grimwade D, Walker H, Oliver F, Wheatley
K, Harrison C, Harrison G, Rees J, Hann I, Stevens R, Burnett A, et
al: The importance of diagnostic cytogenetics on outcome in AML:
Analysis of 1,612 patients entered into the MRC AML 10 trial The
medical research council adult and children's Leukaemia working
parties. Blood. 92:2322–2333. 1998.PubMed/NCBI
|
|
9
|
Yan W, Xu L, Sun Z, Lin Y, Zhang W, Chen
J, Hu S and Shen B: MicroRNA biomarker identification for pediatric
acute myeloid leukemia based on a novel bioinformatics model.
Oncotarget. 6:26424–26436. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Metzeler KH, Dufour A, Benthaus T, Hummel
M, Sauerland MC, Heinecke A, Berdel WE, Büchner T, Wörmann B,
Mansmann U, et al: ER expression is an independent prognostic
factor and allows refined risk stratification in cytogenetically
normal acute myeloid leukemia: A comprehensive analysis of ERG,
MN1, and BAALC transcript levels using oligonucleotide microarrays.
J Clin Oncol. 27:5031–5038. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Aref S, Al Khodary T, Zeed TA, El Sadiek
A, El Menshawy N and Al Ashery R: The prognostic relevance of BAALC
and ERG expression levels in cytogenetically normal pediatric acute
myeloid leukemia. Indian J Hematol Blood Transfus. 31:21–28. 2015.
View Article : Google Scholar
|
|
12
|
Guo X, Shi P, Chen F, Zha J, Liu B, Li R,
Dong H, Zheng H and Xu B: Low MDR1 and BAALC expression identifies
a new subgroup of intermediate cytogenetic risk acute myeloid
leukemia with a favorable outcome. Blood Cells Mol Dis. 53:144–148.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Xiang L, Li M, Liu Y, Cen J, Chen Z, Zhen
X, Xie X, Cao X and Gu W: The clinical characteristics and
prognostic significance of MN gene and MN1-associated microRNA
expression in adult patients with de novo acute myeloid leukemia.
Ann Hematol. 92:1063–1069. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Metzeler KH, Hummel M, Bloomfield CD,
Spiekermann K, Braess J, Sauerland MC, Heinecke A, Radmacher M,
Marcucci G, Whitman SP, et al: An 86-probe-set gene-expression
signature predicts survival in cytogenetically normal acute myeloid
leukemia. Blood. 112:4193–4201. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ritchie ME, Phipson B, Wu D, Hu Y, Law CW,
Shi W and Smyth GK: Limma powers differential expression analyses
for RNA-sequencing and microarray studies. Nucleic Acids Res.
43:e472015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wang P, Wang Y, Hang B, Zou X and Mao JH:
A novel gene expression-based prognostic scoring system to predict
survival in gastric cancer. Oncotarget. 7:55343–55351.
2016.PubMed/NCBI
|
|
17
|
Huang da W, Sherman BT and Lempicki RA:
Systematic and integrative analysis of large gene lists using DAVID
bioinformatics resources. Nat Protoc. 4:44–57. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hudson TJ, Anderson W, Aretz A, Anderson
W, Artez A, Barker AD, Bell C, Bernabé RR, Bhan MK, Calvo F, et al:
International network of cancer genome projects. Nature.
464:993–998. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yang Y, Han L, Yuan Y, Li J, Hei N and
Liang H: Gene co-expression network analysis reveals common
system-level properties of prognostic genes across cancer types.
Nat Commun. 5:32312014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ying H, Lv J, Ying T, Jin S, Shao J, Wang
L, Xu H, Yuan B and Yang Q: Gene-gene interaction network analysis
of ovarian cancer using TCGA data. J Ovarian Res. 6:882013.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Klesney-Tait J, Turnbull IR and Colonna M:
The TREM receptor family and signal integration. Nat Immunol.
7:1266–1273. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lin D, Zhang J, Li J, He H, Deng HW and
Wang YP: Integrative analysis of multiple diverse omics datasets by
sparse group multitask regression. Front Cell Dev Biol. 2:622014.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Benitez BA, Jin SC, Guerreiro R, Graham R,
Lord J, Harold D, Sims R, Lambert JC, Gibbs JR, Bras J, et al:
Missense variant in TREML protects against Alzheimer's disease.
Neurobiol Aging. 35:e19-e262014. View Article : Google Scholar
|
|
24
|
Huang Y, Dai Z, Barbacioru C and Sadée W:
Cystine-glutamate transporter SLC7A11 in cancer chemosensitivity
and chemoresistance. Cancer Res. 65:7446–7454. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lutgen V, Resch J, Qualmann K, Raddatz NJ,
Panhans C, Olander EM, Kong L, Choi S, Mantsch JR and Baker DA:
Behavioral assessment of acute inhibition of system
xc− in rats. Psychopharmacology.
231:4637–4647. 2014. View Article : Google Scholar
|
|
26
|
Chintala S, Li W, Lamoreux ML, Ito S,
Wakamatsu K, Sviderskaya EV, Bennett DC, Park YM, Gahl WA, Huizing
M, et al: Slc7a1 gene controls production of pheomelanin pigment
and proliferation of cultured cells. Proc Natl Acad Sci USA.
102:10964–10969. 2005. View Article : Google Scholar
|
|
27
|
Bridges R, Lutgen V, Lobner D and Baker
DA: Thinking outside the cleft to understand synaptic activity:
Contribution of the cystine-glutamate antiporter (system
xc−) to normal and pathological glutamatergic
signaling. Pharmacol Rev. 64:780–802. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Liu X, Li X, Zhang B, Liang YJ, Zhou CX,
Cao DX, He M, Chen GQ, He JR and Zhao Q: MicroRNA-26b is
underexpressed in human breast cancer and induces cell apoptosis by
targeting SLC7A11. FEBS Lett. 585:1363–1367. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Luo Y, Wang C, Yong P, Ye P, Liu Z, Fu Z,
Lu F, Xiang W, Tan W and Xiao J: Decreased expression of the long
non-coding RNA SLC7A11-AS1 predicts poor prognosis and promotes
tumor growth in gastric cancer. Oncotarget. 8:112530–112549. 2017.
View Article : Google Scholar
|
|
30
|
Tschopp J, Martinon F and Burns K: NALPs:
A novel protein family involved in inflammation. Nat Rev Mol Cell
Biol. 4:95–104. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Hughes FM Jr, Kennis JG, Youssef MN, Lowe
DW, Shaner BE and Purves JT: The NACHT, LRR and PYD
domains-containing protein 3 (NLRP3) inflammasome mediates
inflammation and voiding dysfunction in a
lipopolysaccharide-induced rat model of cystitis. J Clin Cell
Immunol. 7:2016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Leemans JC, Cassel SL and Sutterwala FS:
Sensing damage by the NLRP3 inflammasome. Immunol Rev.
243:1521622011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Yu N, Liu S, Yi X, Zhang S and Ding Y:
Serum amyloid A induces interleukin-1β secretion from keratinocytes
via the NACHT, LRR and PYD domains‑containing protein 3
inflammasome. Clin Exp Immunol. 179:344–353. 2015. View Article : Google Scholar :
|
|
34
|
Wu G, Liao Y, Qin Z, He LR, Chen YC, Zeng
YX, Kung HF and Xie D: PYRIN domain of NALP2 inhibits cell
proliferation and tumor growth of human glioblastoma. Plasmid.
64:41–50. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Li J, Liu D, Wang J, Deng H, Luo X, Shen
X, Huan Y, Huang G and Ye H: Meta‑analysis identifies candidate key
genes in endometrium as predictive biomarkers for clinical
pregnancy in IVF. Oncotarget. 8:102428–102436. 2017.PubMed/NCBI
|
|
36
|
Sato T, Nakashima A, Guo L, Coffman K and
Tamanoi F: Single amino-acid changes that confer constitutive
activation of mTOR are discovered in human cancer. Oncogene.
29:2746–2752. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Sofer A, Lei K, Johannessen CM and Ellisen
LW: Regulation of mTOR and cell growth in response to energy stress
by REDD1. Mol Cell Biol. 25:5834–5845. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Zoncu R, Efeyan A and Sabatini DM: mTOR:
From growth signal integration to cancer, diabetes and ageing. Nat
Rev Mol Cell Biol. 12:21–35. 2011. View Article : Google Scholar
|
|
39
|
Pinto JA, Rolfo C, Raez LE, Prado A,
Araujo JM, Bravo L, Fajardo W, Morante ZD, Aguilar A, Neciosup SP,
et al: In silico evaluation of DNA damage inducible transcript 4
gene (DDIT4) as prognostic biomarker in several malignancies. Sci
Rep. 7:15262017. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Li Y, Guerrero A and Howard TH: The
actin-binding protein, lymphocyte‑specific protein 1, is expressed
in human leukocytes and human myeloid and lymphoid cell lines. J
Immunol. 155:3563–3569. 1995.PubMed/NCBI
|
|
41
|
Howard TH, Hartwig J and Cunningham C:
Lymphocyte‑specific protein 1 expression in eukaryotic cells
reproduces the morphologic and motile abnormality of NAD 47/89
neutrophils. Blood. 91:4786–4795. 1998.PubMed/NCBI
|
|
42
|
Marafioti T, Mancini C, Ascani S,
Sabattini E, Zinzani PL, Pozzobon M, Pulford K, Falini B, Jaffe ES,
Müller- Hermelink HK, et al: Leukocyte‑specific phosphoprotein‑1
and PU. 1: Two useful markers for distinguishing T-cell-rich B-cell
lymphoma from lymphocyte-predominant Hodgkin's disease.
Haematologica. 89:957–964. 2004.PubMed/NCBI
|
|
43
|
Couch FJ, Wang X, McWilliams RR, Bamlet
WR, de Andrade M and Petersen GM: Association of breast cancer
susceptibility variants with risk of pancreatic cancer. Cancer
Epidemiol Biomarkers Prev. 18:3044–3048. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Chen H, Qi X, Qiu P and Jhao J:
Correlation between LSP1 polymorphisms and the susceptibility to
breast cancer. Int J Clin Exp Pathol. 8:5798–5802. 2015.PubMed/NCBI
|
|
45
|
Jin SY, Choi JS, Choi YL, Choi YL, Kim DH
and Lee SH: Identification of leukocyte‑specific protein 1‑positive
cells: A clue to the cell of origin and a marker for the diagnosis
of dermatofibroma. Ann Dermatol. 27:1571622015. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Zhang H, Wang Y, Liu Z, Yao B, Dou C, Xu
M, Li Q, Jia Y, Wu S, Tu K and Liu Q: Lymphocyte‑specific protein 1
inhibits the growth of hepatocellular carcinoma by suppressing
ERK1/2 phosphorylation. FEBS Open Bio. 6:1227–1237. 2016.
View Article : Google Scholar
|
|
47
|
Stone J, Thompson DJ, dos Santos Silva I,
Scott C, Tamimi RM, Lindstrom S, Kraft P, Hazra A, Li J, Eriksson
L, et al: Novel associations between common breast cancer
susceptibility variants and risk-predicting mammographic density
measures. Cancer Res. 75:2457–2567. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Bannwarth S, Giordanengo V, Lesimple J and
Lefebvre JC: Molecular cloning of a new secreted sulfated
mucin-like protein with a C-type lectin domain that is expressed in
lymphoblastic cells. J Biol Chem. 273:1911–1916. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Hiraoka A, Sugimura A, Seki T, Nagasawa T,
Ohta N, Shimonishi M, Hagiya M and Shimizu S: Cloning, expression,
and characterization of a cDNA encoding a novel human growth factor
for primitive hematopoietic progenitor cells. Proc Nat Acad Sci
USA. 94:7577–7582. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Hiraoka A, Yano KI K, Kagami N, Takeshige
K, Mio H, Anazawa H and Sugimoto S: Stem cell growth factor: In
situ hybridization analysis on the gene expression, molecular
characterization and in vitro proliferative activity of a
recombinant preparation on primitive hematopoietic progenitor
cells. Hematol J. 2:307–315. 2001. View Article : Google Scholar
|
|
51
|
Yue R, Shen B and Morrison SJ:
Clec11a/osteolectin is an osteogenic growth factor that promotes
the maintenance of the adult skeleton. Elife. 5:e187822016.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Hur K, Toiyama Y, Boland CR and Goel A:
468 Serum microRNA-885-5p is a novel prognostic and
metastasis-predictive biomarker in patients with colorectal cancer.
Gastroenterol. 144:735–743. 2013. View Article : Google Scholar
|
|
53
|
Perumal D, Lagana A, Melnekoff D, Readhead
B, Kidd B, Leshchenko VV, Kuo P-Y, Yesil J, Derome M, Auclair D, et
al: Network Modeling Reveals CDC42BP and CLEC11A As Novel Driver
Genes of t(4; 14) Multiple Myeloma. Am Soc Hematol.
128:8022016.
|
|
54
|
Ito C, Sato H, Ando K, Watanabe S, Yoshiba
F, Kishi K, Furuya A, Shitara K, Sugimoto S, Kohno H, et al: Serum
stem cell growth factor for monitoring hematopoietic recovery
following stem cell transplantation. Bone Marrow Transplant.
32:391–398. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Keller CC, Ouma C, Ouma Y, Awandare GA,
Davenport GC, Were T, Hittner JB, Vulule JM, Ong'echa JM and
Perkins DJ: Suppression of a novel hematopoietic mediator in
children with severe malarial anemia. Infect Immun. 77:3864–3871.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
de Bruijn MF and Speck NA: Core-binding
factors in hematopoiesis and immune function. Oncogene.
23:4238–4248. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Wickramarachchi DC, Theofilopoulos AN and
Kono DH: Immune pathology associated with altered actin
cytoskeleton regulation. Autoimmunity. 43:64–75. 2010. View Article : Google Scholar
|
